TOP STORIES
Updates on COVID-19 vaccine candidates, FDA policies, company partnerships, and more.
/ read more /
|
|
The company closed two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, for a total of $1.46 billion combined.
/ read more /
|
|
ADVERTISEMENT
BIO International Convention
Take your business BEYOND expectations at the world's largest biotechnology partnering event! Join over 17,000 biotech and pharma professionals from around the world for four days of BIO One-on-One Partnering, world-class education sessions, and the expansive BIO Exhibition featuring 1,800+ innovative companies.
Learn More »  |
|
SubscribeSubscribers can enjoy each full issue of BioPharm International in print, or via BioPharm apps.
subscription offers
|
|
| |
advertisement
|
|
Industry News
The medical service volunteer programs will allow their employees who are licensed medical professionals to help fight against COVID-19 while maintaining their base pay.
/ read more /
The event, which was originally scheduled for May 11–13, 2020 at the Gaylord Palms Resort and Convention Center in Kissimmee, FL, will be canceled due to concerns regarding the spread of COVID-19.
/ read more /
MORE INDUSTRY NEWS
|
advertisement
|
| |
|
ADVERTISEMENT
Featured Resources from BioPharm International
View our online resource center, sponsored by GE Healthcare, to explore a case study and articles on gaining and retaining skilled labor, modular bioprocessing, the good and bad of biosilimiars, and more.
Learn More »  |
Biopharma News
The companies are entering into a partnership to develop fully human neutralizing antibodies targeting SARS-CoV-2 to prevent or treat COVID-19.
/ read more /
The patent includes the use of fibroblast cells and adjuvants such as peptides and hydroxychloroquine, which fuels the assembly of natural interferon to overpower the virus.
/ read more /
More Biopharma News
|
|
| |
|
Supplier News
Suppliers to the bio/pharma industry are sharing news about the business operations during the global COVID-19 pandemic. To view current information about the company’s business operations, click the company name.
/ read more /
|
|
Daiichi Sankyo has entered into a partnership with Ultragenyx Pharmaceutical for the use of Ultragenyx’s proprietary AAV-based gene-therapy manufacturing technology.
/ read more /
More Supplier News
|
|
Regulatory News
The bill includes multiple less-noticed provisions to bolster healthcare programs and to advance the development of new treatments and preventives to combat the virus.
/ read more /
|
With new tests showing NDMA levels increase under normal storage conditions, FDA calls for removal of ranitidine products from the market.
/ read more /
More Regulatory News
|
|
FEATURED TOPICS |
|
PEER-REVIEWED RESEARCH
The authors present a risk analysis of the impact of various business and operating risks on three facility layout strategies.
/ read more /
|
|
|
|
|
ANALYTICAL METHODS
Oligonucleotides, which are classified as both small molecules and biomolecules, pose unique analytical challenges. High-resolution mass spectrometry is becoming a method of choice for their development.
/ read more /
|
|
|
|
|
MANUFACTURING
Despite the growing popularity of single-use technologies in biomanufacturing, there are still instances where stainless steel is the better option.
/ read more /
|
|
|
|
Rescheduled Events
CPhI South East Asia has been rescheduled for July 2020.
Interphex 2020 has been rescheduled for July 2020.
PDA’s Annual Meeting has been rescheduled for July 2020.
Bioprocessing Summit Europe has been rescheduled for July 2020.
PDA’s Pharmaceutical Manufacturing Data Science Workshop has been rescheduled for July 2020.
CPhI North America has been rescheduled for September 2020.
CPhI Japan has been rescheduled for September 2020.
Analytica 2020 has been rescheduled for October 2020.
Interpack 2020 has been rescheduled for February 2021.
more events
|
|
|
eBook
|
In BioPharm International’s Pharmacopoeia Compliance Series, experts explain the revision process for global and national pharmacopoeias, best practices for monitoring changes, and how to participate in revisions. Other features include FDA warning letters, FDA Form 483s, and essentials for quality risk management.
|
|
|
|
| |
